drugset / Trial / NCT05301842
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
RandomizedParallel-groupSingle-blindTreatment
Summary
A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Timeline
- Start
- 2022-03-28
- Primary completion
- 2026-02-23
- Completion
- 2027-02-26
Outcome
Met primary endpoint
release “EMERALD‑3 shows we can now significantly reduce the risk of disease progression with STRIDE as the immunotherapy backbone alongside lenvatinib and TACE.” astrazeneca.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |